

***Acute and Chronic Leukemia:  
Practical Applications 2024  
October 11-12, 2024***

**Friday, October 11, 2024**

---

10:00 a.m.	<b>Registration and Exhibits</b>
11:00 a.m.	<b>Welcome Announcements</b> Lisa Z. Sproat, M.D.
11:15 a.m.	<b>Keynote Address:</b> <b>AML: What is New on the Horizon</b> James M. Foran, M.D.
11:45 a.m.	<b>Q &amp; A</b>
12:00 p.m.	<b>Lunch and Exhibits</b>
<b>SESSION:</b>	<b>AML</b>
<b>MODERATOR:</b>	James M. Foran, M.D.
1:00 p.m.	<b>Acute Myeloid Leukemia: Using Targeting Therapies in Current Practice (addressing FLT3, IDH 1 and 2)</b> <b>Moderator:</b> Lisa Z. Sproat, M.D. <b>Panel:</b> James M. Foran, M.D.; Cecilia Y. Arana Yi, M.D.; Kebede H. Begna, M.D.; Aref Al Kali, M.D. <b>Hematopathologist:</b> Rong He, M.D.
1:45 p.m.	<b>Q &amp; A</b> Session Faculty
2:00 p.m.	<b>The Great Debate: Intensive vs. Less Intensive Chemotherapy Approach</b> William J. Hogan, M.B., B.Ch. and Cecilia Y. Arana Yi, M.D.
3:00 p.m.	<b>Q &amp; A</b>
3:15 p.m.	<b>Refreshment Break and Exhibits</b>

**Friday, October 11, 2024 (continued)**

---

- 3:45 p.m.            **TP53 Mutated Myeloid Neoplasms**  
Mithun V. Shah, M.D., Ph.D.
- 4:15 p.m.            **Innovative Strategies for Relapsed/Refractory AML**  
Kebede H. Begna, M.D.
- 4:45 p.m.            **VEXAS Syndrome: Diagnostic, Prognostic and  
Treatment Implications**  
Abhishek A. Mangaonkar, M.B.B.S.
- 5:15 p.m.            **Q & A**  
Session Faculty
- 5:30 p.m.            **Adjourn**

## Saturday, October 12, 2024

---

- 7:00 a.m.            **Breakfast and Exhibits**
- 7:45 a.m.            **Welcome Announcements**  
Lisa Z. Sproat, M.D.
- SESSION:**            **Case Based Presentations for Cutting Edge Therapy**
- MODERATOR:**        Lisa Z. Sproat, M.D.
- 8:00 a.m.            **CML (from chronic to accelerated to TFR)**  
Talha Badar, M.B.B.S, M.D.
- 8:30 a.m.            **Myeloproliferative Neoplasm: Choosing the  
Best Drug for Your Patient**  
Naseema Gangat, M.B.B.S. and  
Kristen B. McCullough, Pharm D., R.Ph.
- 9:00 a.m.            **What to do when JAK2 Inhibitors Fail**  
Jeanne M. Palmer, M.D.
- 9:30 a.m.            **Case Based Q and A**  
Session Faculty
- 10:00 a.m.           **Refreshment Break and Exhibits**
- SESSION:**            **Myelodysplastic Syndrome (MDS)**
- MODERATOR:**        Kebede H. Begna, M.D.
- 10:30 a.m.           **Lower Risk MDS: Practical Applications of  
Growth Factors for Anemia and Cytopenias**  
Aref Al-Kali, M.D.
- 11:00 a.m.           **High Risk MDS/Therapy Related Myeloid Neoplasm:  
Practical Applications of Combined Therapy and  
Integration of Allogeneic Stem Cell Transplant**  
Nathan Punwani, M.D.
- 11:30 a.m.           **Q & A**
- 12:00 p.m.           **Lunch and Exhibits**

**Saturday, October 12, 2024** *(continued)*

---

**SESSION:** Acute Lymphoblastic Leukemia

**MODERATOR:** Kebede H. Begna, M.D.

1:00 p.m. **Evolution of ALL Therapy in Adults**  
Antoine N. Saliba, M.D.

1:30 p.m. **ALL in the Adolescents and Young Adults**  
Madeleine B. O'Keefe M.D.

2:00 p.m. **Novel Leukemia Diagnostics and MRD in ALL**  
Dragan Jevremovic, M.D., Ph.D.

2:30 p.m. **Q & A**

3:00 p.m. **Closing Remarks/Adjourn**